1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 32
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.3.2 YEARS CONSIDERED FOR THE STUDY 33
1.4 CURRENCY 33
1.5 LIMITATIONS 33
1.6 STAKEHOLDERS 33
1.7 SUMMARY OF CHANGES 34
1.8 LIMITATIONS OF THE CURRENT EDITION 34

2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 36
2.1.2 PRIMARY DATA 36
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 37
2.1.2.1 Key data from primary sources 37
2.2 MARKET SIZE ESTIMATION 38
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 38
2.2.1 BOTTOM-UP APPROACH 39
FIGURE 4 OSTEOARTHRITIS THERAPEUTICS MARKET: BOTTOM-UP APPROACH 39
2.2.2 GROWTH FORECAST 40
2.2.3 TOP-DOWN APPROACH 40
FIGURE 5 OSTEOARTHRITIS THERAPEUTICS MARKET: TOP-DOWN APPROACH 40
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 41
FIGURE 6 DATA TRIANGULATION METHODOLOGY 41
2.4 ASSUMPTIONS FOR THE STUDY 42

3 EXECUTIVE SUMMARY 43
FIGURE 7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,

2020 VS. 2025 (USD BILLION) 43
FIGURE 8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,

2020 VS. 2025 (USD BILLION) 44
FIGURE 9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS. 2025 (USD BILLION) 45
FIGURE 10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020 VS. 2025 (USD BILLION) 45
FIGURE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN,

2020 VS. 2025 (USD BILLION) 46
FIGURE 12 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,

2020 VS. 2025 (USD BILLION) 47

4 PREMIUM INSIGHTS 48
4.1 OSTEOARTHRITIS THERAPEUTICS MARKET OVERVIEW 48
FIGURE 13 INCREASING PREVALENCE OF OSTEOARTHRITIS IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET 48
4.2 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY DRUG TYPE (2019) 49
FIGURE 14 VISCOSUPPLEMENTATION AGENTS SEGMENT TO DOMINATE THE EUROPEAN MARKET IN 2020 49
4.3 GEOGRAPHICAL SNAPSHOT OF THE OSTEOARTHRITIS THERAPEUTICS MARKET 50
FIGURE 15 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
IN THE OSTEOARTHRITIS THERAPEUTICS MARKET 50

5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 16 OSTEOARTHRITIS THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
5.2.1 DRIVERS 51
5.2.1.1 Significant adoption of pain medications 51
5.2.1.2 Increasing prevalence of osteoarthritis 52
5.2.1.3 Growing population susceptible to osteoarthritis 52
FIGURE 17 SHARE OF OBESE ADULTS, BY REGION (2016) 53
5.2.1.4 Rising number of sports injuries 53
FIGURE 18 INJURIES CAUSED BY SPORTS ACTIVITIES IN THE US (2019) 54
5.2.2 RESTRAINTS 55
5.2.2.1 Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment 55
5.2.2.2 Commercialization of alternatives 55
5.2.3 OPPORTUNITIES 55
5.2.3.1 Personalized medicines for osteoarthritis 55
5.2.3.2 Emerging markets 56
5.2.3.3 Collaborations for product development 56
5.2.4 CHALLENGES 56
5.2.4.1 Adoption of non-drug pain management therapies 56
5.3 VALUE CHAIN ANALYSIS 57
FIGURE 19 VALUE CHAIN ANALYSIS: PHARMACEUTICALS INDUSTRY 57
TABLE 1 COSTS INCURRED AND VALUE ADDED ACROSS THE VALUE CHAIN,
BY COMPONENT 58
5.4 SUPPLY CHAIN ANALYSIS 58
FIGURE 20 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF PROMINENT COMPANIES 59
5.5 ECOSYSTEM ANALYSIS 60
FIGURE 21 ECOSYSTEM ANALYSIS 60
5.6 COVID-19 IMPACT ANALYSIS ON THE OSTEOARTHRITIS THERAPEUTICS MARKET 61
5.7 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF OSTEOARTHRITIS DRUGS 61
5.8 REGULATORY SCENARIO 62
TABLE 3 LIST OF REGULATORY AUTHORITIES IN THE PHARMA INDUSTRY 62
5.8.1 REGULATORY REQUIREMENTS 63
5.8.1.1 EU regulations 63
5.8.1.2 US regulations 63
5.9 EPIDEMIOLOGY (PATIENT POPULATION) 64
5.9.1 SEVERITY 64
TABLE 4 COUNTRY-WISE OSTEOARTHRITIS EPIDEMIOLOGY, BY SEVERITY (2019) 65
5.9.2 ANATOMY 66
TABLE 5 COUNTRY-WISE OSTEOARTHRITIS EPIDEMIOLOGY, BY ANATOMY (2019) 66

6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY 67
6.1 INTRODUCTION 68
TABLE 6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 68
6.2 KNEE OSTEOARTHRITIS 68
6.2.1 RISING OBESE AND GERIATRIC POPULATIONS TO INCREASE THE PREVALENCE OF KNEE OSTEOARTHRITIS 68
TABLE 7 KNEE OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2018-2025 (USD MILLION) 69
6.3 HIP OSTEOARTHRITIS 69
6.3.1 SIMILAR TO KNEE OSTEOARTHRITIS, HIP OSTEOARTHRITIS IS MORE COMMON IN THE GERIATRIC AND OBESE POPULATIONS 69
TABLE 8 HIP OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2018-2025 (USD MILLION) 69
6.4 HAND OSTEOARTHRITIS 70
6.4.1 RISING PREVALENCE OF SHOULDER OSTEOARTHRITIS TO DRIVE MARKET GROWTH 70
TABLE 9 HAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2018-2025 (USD MILLION) 70
6.5 SMALL JOINT OSTEOARTHRITIS 71
6.5.1 RISING NUMBER OF ANKLE-RELATED SPORTS INJURIES TO INCREASE THE PREVALENCE OF ANKLE OSTEOARTHRITIS 71
TABLE 10 SMALL JOINT OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2018-2025 (USD MILLION) 71

7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE 72
7.1 INTRODUCTION 73
TABLE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 73
7.2 VISCOSUPPLEMENTATION AGENTS 73
7.2.1 VISCOSUPPLEMENTATION AGENTS DOMINATED THE MARKET IN 2019 73
TABLE 12 OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2018-2025 (USD MILLION) 74
7.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 74
7.3.1 NSAIDS CAN RELIEVE PAIN AND INFLAMMATION WITHOUT THE ADVERSE EFFECTS OF CORTICOSTEROIDS 74
TABLE 13 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 74
TABLE 14 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2025 (USD MILLION) 75
7.3.1.1 Ibuprofen 75
TABLE 15 OSTEOARTHRITIS THERAPEUTICS MARKET FOR IBUPROFEN, BY REGION, 2018-2025 (USD MILLION) 75
7.3.1.2 Aspirin 76
TABLE 16 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ASPIRIN, BY REGION,
2018-2025 (USD MILLION) 76
7.3.1.3 Diclofenac 76
TABLE 17 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DICLOFENAC, BY REGION, 2018-2025 (USD MILLION) 76
7.3.1.4 Naproxen 77
TABLE 18 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NAPROXEN, BY REGION, 2018-2025 (USD MILLION) 77
7.3.1.5 Other NSAIDs 77
TABLE 19 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OTHER NSAIDS, BY REGION, 2018-2025 (USD MILLION) 77
7.4 ANALGESICS 78
7.4.1 ACETAMINOPHEN HOLDS THE LARGEST SHARE OF THE ANALGESICS MARKET 78
TABLE 20 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 78
TABLE 21 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION, 2018-2025 (USD MILLION) 78
7.4.1.1 Acetaminophen 79
TABLE 22 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ACETAMINOPHEN,
BY REGION, 2018-2025 (USD MILLION) 79
7.4.1.2 Duloxetine 79
TABLE 23 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DULOXETINE, BY REGION, 2018-2025 (USD MILLION) 79
7.5 CORTICOSTEROIDS 80
7.5.1 EUROPE AND NORTH AMERICA ARE THE LARGEST MARKETS FOR CORTICOSTEROIDS 80
TABLE 24 OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS,
BY REGION, 2018-2025 (USD MILLION) 80

8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION 81
8.1 INTRODUCTION 82
TABLE 25 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 82
8.2 PARENTERAL ROUTE 82
8.2.1 DRUGS INEFFECTIVE WHEN ADMINISTERED ORALLY CAN BE DELIVERED VIA PARENTERAL ROUTE 82
TABLE 26 PARENTERAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2018-2025 (USD MILLION) 82
8.3 ORAL ROUTE 83
8.3.1 ORAL ROUTE IS WIDELY PREFERRED BY BOTH CLINICIANS AND PATIENTS 83
TABLE 27 ORAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2018-2025 (USD MILLION) 83
8.4 TOPICAL ROUTE 83
8.4.1 EASE OF USE, PAINLESS AND NON-INVASIVE ADMINISTRATION HAVE SUPPORTED USE OF TOPICAL ROUTE 83
TABLE 28 TOPICAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2018-2025 (USD MILLION) 84

9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 85
9.1 INTRODUCTION 86
TABLE 29 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 86
9.2 HOSPITAL PHARMACIES 86
9.2.1 HOSPITAL PHARMACIES ARE THE LARGEST DISTRIBUTION CHANNEL FOR OSTEOARTHRITIS THERAPEUTICS 86
TABLE 30 OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES,
BY REGION, 2018-2025 (USD MILLION) 86
9.3 RETAIL PHARMACIES 87
9.3.1 GREATER PREFERENCE FOR RETAIL PHARMACIES HAS AFFECTED MARKET SHARE 87
TABLE 31 OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES,
BY REGION, 2018-2025 (USD MILLION) 87
9.4 ONLINE PHARMACIES 87
9.4.1 ONLINE PHARMACIES TO REGISTER THE HIGHEST GROWTH 87
TABLE 32 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES,
BY REGION, 2018-2025 (USD MILLION) 88

10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN 89
10.1 INTRODUCTION 90
TABLE 33 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 90
10.2 PRESCRIPTION DRUGS 90
10.2.1 PRESCRIPTION DRUGS TO ACCOUNT FOR A LARGER SHARE OF THE MARKET 90
TABLE 34 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PRESCRIPTION DRUGS,
BY REGION, 2018-2025 (USD MILLION) 90
10.3 OVER-THE-COUNTER DRUGS 91
10.3.1 EASE OF PURCHASE AND ADMINISTRATION ARE RESULTING IN A RISING DEMAND FOR OTC DRUGS 91
TABLE 35 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2018-2025 (USD MILLION) 91

11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION 92
11.1 INTRODUCTION 93
TABLE 36 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2018-2025 (USD MILLION) 93
11.2 EUROPE 93
FIGURE 22 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT 94
TABLE 37 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY,
2018-2025 (USD MILLION) 95
TABLE 38 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 95
TABLE 39 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 95
TABLE 40 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 96
TABLE 41 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 96
TABLE 42 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 96
TABLE 43 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 97
TABLE 44 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 97
11.2.1 ITALY 97
11.2.1.1 Italy dominates the European market for osteoarthritis therapeutics 97
TABLE 45 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 98
TABLE 46 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 98
TABLE 47 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 98
TABLE 48 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 99
TABLE 49 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 99
TABLE 50 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 99
TABLE 51 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 100
11.2.2 GERMANY 100
11.2.2.1 Road accidents in the country to propel the demand for osteoarthritis therapeutics 100
TABLE 52 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 100
TABLE 53 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 101
TABLE 54 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2018-2025 (USD MILLION) 101
TABLE 55 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 101
TABLE 56 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 102
TABLE 57 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 102
TABLE 58 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 102
11.2.3 SPAIN 103
11.2.3.1 High prevalence of osteoarthritis to drive the growth of the market 103
TABLE 59 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 103
TABLE 60 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 103
TABLE 61 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 104
TABLE 62 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 104
TABLE 63 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 104
TABLE 64 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 105
TABLE 65 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 105
11.2.4 FRANCE 105
11.2.4.1 Rising geriatric population to accelerate the growth of the market during the forecast period 105
TABLE 66 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 105
TABLE 67 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 106
TABLE 68 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2018-2025 (USD MILLION) 106
TABLE 69 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 106
TABLE 70 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 107
TABLE 71 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 107
TABLE 72 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 107
11.2.5 UK 107
11.2.5.1 Increasing obesity rate and rising incidence of musculoskeletal diseases drive the market in the UK 107
TABLE 73 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 108
TABLE 74 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 108
TABLE 75 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 108
TABLE 76 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 109
TABLE 77 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 109
TABLE 78 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 109
TABLE 79 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 110
11.2.6 REST OF EUROPE 110
TABLE 80 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 110
TABLE 81 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 111
TABLE 82 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 111
TABLE 83 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 111
TABLE 84 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 112
TABLE 85 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 112
TABLE 86 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 112
11.3 NORTH AMERICA 113
TABLE 87 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION) 113
TABLE 88 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION) 113
TABLE 89 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION) 113
TABLE 90 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 114
TABLE 91 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE,
2018-2025 (USD MILLION) 114
TABLE 92 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 114
TABLE 93 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 115
TABLE 94 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 115
11.3.1 US 115
11.3.1.1 The US holds the largest share in the North American market 115
TABLE 95 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 116
TABLE 96 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 116
TABLE 97 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 116
TABLE 98 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 117
TABLE 99 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 117
TABLE 100 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 117
TABLE 101 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 118
11.3.2 CANADA 118
11.3.2.1 Rising geriatric and obese populations will drive the incidence of osteoarthritis therapeutics 118
TABLE 102 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 118
TABLE 103 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 119
TABLE 104 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 119
TABLE 105 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 119
TABLE 106 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 120
TABLE 107 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 120
TABLE 108 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 120
11.4 ASIA PACIFIC 121
FIGURE 23 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT 121
TABLE 109 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION) 122
TABLE 110 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION) 122
TABLE 111 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION) 122
TABLE 112 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 123
TABLE 113 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE,
2018-2025 (USD MILLION) 123
TABLE 114 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 123
TABLE 115 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 124
TABLE 116 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 124
11.4.1 JAPAN 124
11.4.1.1 Japan dominates the osteoarthritis therapeutics market in the APAC 124
TABLE 117 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 125
TABLE 118 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 125
TABLE 119 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2018-2025 (USD MILLION) 125
TABLE 120 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 126
TABLE 121 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 126
TABLE 122 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 126
TABLE 123 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 127
11.4.2 CHINA 127
11.4.2.1 Rising geriatric population to propel the demand for osteoarthritis therapeutics in China 127
TABLE 124 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 127
TABLE 125 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 128
TABLE 126 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 128
TABLE 127 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 128
TABLE 128 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 129
TABLE 129 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 129
TABLE 130 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 129
11.4.3 INDIA 130
11.4.3.1 Rising prevalence of osteoarthritis to accelerate market growth in India 130
TABLE 131 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 130
TABLE 132 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 130
TABLE 133 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 131
TABLE 134 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 131
TABLE 135 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 131
TABLE 136 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 132
TABLE 137 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 132
11.4.4 SOUTH KOREA 132
11.4.4.1 Initiatives by market players to support the growth of the market 132
TABLE 138 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION) 133
TABLE 139 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION) 133
TABLE 140 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 133
TABLE 141 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE,
2018-2025 (USD MILLION) 134
TABLE 142 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 134
TABLE 143 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 134
TABLE 144 SOUTH KOREA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 135
11.4.5 AUSTRALIA 135
11.4.5.1 Prevalence of osteoarthritis to accelerate the growth of the market 135
TABLE 145 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 135
TABLE 146 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION) 136
TABLE 147 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 136
TABLE 148 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 136
TABLE 149 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 137
TABLE 150 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 137
TABLE 151 AUSTRALIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 137
11.4.6 REST OF ASIA PACIFIC 137
TABLE 152 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 138
TABLE 153 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 138
TABLE 154 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2018-2025 (USD MILLION) 138
TABLE 155 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 139
TABLE 156 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 139
TABLE 157 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 139
TABLE 158 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 140
11.5 REST OF THE WORLD 140
TABLE 159 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2018-2025 (USD MILLION) 140
TABLE 160 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2018-2025 (USD MILLION) 140
TABLE 161 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2018-2025 (USD MILLION) 141
TABLE 162 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2018-2025 (USD MILLION) 141
TABLE 163 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 141
TABLE 164 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 142
TABLE 165 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 142
TABLE 166 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 142
11.5.1 LATIN AMERICA 142
11.5.1.1 Latin America holds a larger share of the RoW market 142
TABLE 167 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2018-2025 (USD MILLION) 143
TABLE 168 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION) 143
TABLE 169 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 143
TABLE 170 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE,
2018-2025 (USD MILLION) 144
TABLE 171 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 144
TABLE 172 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 144
TABLE 173 LATIN AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 145
11.5.2 MIDDLE EAST AND AFRICA 145
11.5.2.1 Rising obesity rates to propel market growth 145
TABLE 174 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ANATOMY, 2018-2025 (USD MILLION) 145
TABLE 175 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DRUG TYPE, 2018-2025 (USD MILLION) 145
TABLE 176 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2018-2025 (USD MILLION) 146
TABLE 177 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2018-2025 (USD MILLION) 146
TABLE 178 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION) 146
TABLE 179 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION) 147
TABLE 180 MIDDLE EAST AND AFRICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY PURCHASING PATTERN, 2018-2025 (USD MILLION) 147

12 COMPETITIVE LANDSCAPE & COMPANY PROFILES 148
12.1 COMPETITIVE LANDSCAPE 148
12.1.1 OVERVIEW 148
FIGURE 24 KEY DEVELOPMENTS IN THE OSTEOARTHRITIS THERAPEUTICS MARKET, JANUARY 2017-NOVEMBER 2020 148
FIGURE 25 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO NOVEMBER 2020 149
12.1.2 COMPETITIVE SCENARIO 150
12.1.2.1 Product launches and approvals 150
TABLE 181 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017?NOVEMBER 2020 150
12.1.2.2 Collaborations and agreements 150
TABLE 182 KEY COLLABORATIONS AND AGREEMENTS, JANUARY 2017?NOVEMBER 2020 150
12.1.2.3 Expansions 151
TABLE 183 KEY EXPANSIONS, JANUARY 2017?NOVEMBER 2020 151
12.1.2.4 Mergers and acquisitions 151
TABLE 184 KEY MERGERS AND ACQUISITIONS, JANUARY 2017?NOVEMBER 2020 151
12.1.2.5 Other developments 152
TABLE 185 OTHER DEVELOPMENTS, JANUARY 2017?NOVEMBER 2020 152
12.1.3 VISCOSUPPLEMENTATION AGENTS MARKET SHARE ANALYSIS, 2019 152
FIGURE 26 VISCOSUPPLEMENTATION AGENTS MARKET SHARE ANALYSIS, 2019 152
12.1.4 COMPANY EVALUATION MATRIX 153
12.1.4.1 Stars 153
12.1.4.2 Emerging leaders 153
12.1.4.3 Pervasive companies 153
12.1.4.4 Participants 153
FIGURE 27 OSTEOARTHRITIS THERAPEUTICS MARKET (GLOBAL) COMPANY EVALUATION MATRIX, 2019 154
12.2 COMPANY PROFILES 155
(Business overview, Products offered, Recent Developments, SWOT analysis, MNM view)*
12.2.1 PFIZER, INC. 155
FIGURE 28 PFIZER, INC.: COMPANY SNAPSHOT (2019) 155
12.2.2 HORIZON THERAPEUTICS PLC 157
FIGURE 29 HORIZON THERAPEUTICS PLC: COMPANY SNAPSHOT (2019) 157
12.2.3 SANOFI 159
FIGURE 30 SANOFI: COMPANY SNAPSHOT (2019) 159
12.2.4 JOHNSON & JOHNSON 161
FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019) 161
12.2.5 BAYER AG 163
FIGURE 32 BAYER AG: COMPANY SNAPSHOT (2019) 163
12.2.6 ABBOTT 165
FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2019) 165
12.2.7 GLAXOSMITHKLINE PLC 166
FIGURE 34 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019) 166
12.2.8 ZIMMER BIOMET HOLDINGS 168
FIGURE 35 ZIMMER BIOMET HOLDINGS, INC.: COMPANY SNAPSHOT (2019) 168
12.2.9 NOVARTIS AG 169
FIGURE 36 NOVARTIS: COMPANY SNAPSHOT (2019) 169
12.2.10 FLEXION THERAPEUTICS, INC. 171
FIGURE 37 FLEXION THERAPEUTICS: COMPANY SNAPSHOT (2019) 171
12.2.11 ANIKA THERAPEUTICS 173
FIGURE 38 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2019) 173
12.2.12 ELI LILLY 175
FIGURE 39 ELI LILLY: COMPANY SNAPSHOT (2019) 175
12.2.13 HANMI PHARM. CO., LTD. 177
FIGURE 40 HANMI PHARM.CO., LTD.: COMPANY SNAPSHOT (2019) 177
12.2.14 ASSERTIO THERAPEUTICS, INC. 178
FIGURE 41 ASSERTIO THERAPEUTICS: COMPANY SNAPSHOT (2019) 178
12.2.15 LABORATORIO REIG JOFRE 179
FIGURE 42 LABORATORIO REIG JOFRE: COMPANY SNAPSHOT (2019) 179
12.2.16 KITOV PHARMACEUTICALS 180
FIGURE 43 KITOV PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2019) 180
12.2.17 VIRCHOW BIOTECH 182
12.2.18 FERRING PHARMACEUTICALS 183
12.2.19 BIOVENTUS 184
12.2.20 ALMATICA PHARMA LLC 186
12.2.21 ATNAHS 187
12.2.22 PHARMED LIMITED 188
12.2.23 ORTHOGENRX 189
12.2.24 LABRHA 190
12.2.25 FIDIA FARMACEUTICI S.P.A. 191
*Details on Business overview, Products offered, Recent Developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.

13 APPENDIX 192
13.1 INDUSTRY INSIGHTS 192
13.2 DISCUSSION GUIDE 193
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 198
13.4 AVAILABLE CUSTOMIZATIONS 200
13.5 RELATED REPORTS 200
13.6 AUTHOR DETAILS 201